Company / Cash & Equivalents
NEUROONE MEDICAL TECHNOLOGIES Corp Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$6.6M
FY2025
5-year range
$1.5M / $8.2M
FY2021-FY2025
Trend
+350.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +350% YoY in FY2025, a notable deviation from the 4-year average annual change of +86%.
Based on SEC 10-K filings.
$7M in FY2025 with a 3-year CAGR of -7.0%.
Improved from $5M to $7M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -7.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -7.0%, indicating a declining trend.
- In FY2025, cash & equivalents increased 350.0% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -2.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.6M | +350.0% |
| FY2024 | $1.5M | -72.6% |
| FY2023 | $5.3M | -34.8% |
| FY2022 | $8.2M | +102.2% |
| FY2021 | $4.0M | - |
| FY2016 | - | - |
| FY2015 | - | - |
| FY2014 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026